Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 801–900 of 1,001
Masarone, D., Pacileo, R., & Pacileo, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10189-4 · Cited by 7
Lin, C., Cai, X., & Ji, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14596 · Cited by 7
Leening, M. J. G., & Mahmoud, K. D. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00820-x · Cited by 7
“However, we encountered 6 trials with a placebo arm as the usual care group [18, 29, 30, 34, 38, 55].”
MethodMoulton, M. K., Johnson, B. R., Lavender, D. L., Osae, S. P., Phillips, B. B., Thomas, I., & Stone, R. H. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211071089 · Cited by 7
Trends in add-on medications following metformin monotherapy for type 2 diabetes
Swart, E. C. S., Neilson, L. M., Munshi, K. D., Peasah, S. K., Henderson, R. R., & Good, C. B. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.11.1253 · Cited by 7
Ji, L., Jiang, X., Hao, Q., Cheng, Z., Wang, K., Pang, S., Liu, M., Guo, Y., Chen, X., Su, X., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14971 · Cited by 7
“A series of studies have shown cardiovascular benefits of SGLT2 inhibitors.(25-29) Empagliflozin, canagliflozin and dapagliflozin are approved for reducing MACE, adverse renal outcomes and risk of hospitalization for heart failure in T2DM patients.”
BackgroundAvgerinos, I., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15200 · Cited by 8
“Of note, patients treated with MRAs were excluded from the Canagliflozin Cardiovascular Assessment Study (CANVAS) programme,(6) while ARNIs had not been commercially approved during the planning of five trials.(4,6,13,15,18) Finally, in the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabe…”
MethodSong, J., Li, X., & Ni, J. (2023) · Kidney & Blood Pressure Research · doi:10.1159/000534174 · Cited by 8
Risk of heart failure in ambulatory resistant hypertension: a meta-analysis of observational studies
Coccina, F., Salles, G. F., Banegas, J. R., Hermida, R. C., Bastos, J. M., Cardoso, C. R. L., Salles, G. C., Sánchez-Martínez, M., Mojón, A., Fernández, J. R., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01632-8 · Cited by 8
Chee, Y. J., & Dalan, R. (2024) · Biomedicines · doi:10.3390/biomedicines12071386 · Cited by 10
Singh, A. K., & Singh, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108536 · Cited by 7
Al‐Sofiani, M. E., Batais, M. A., Aldhafiri, E., & Alzaid, A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.003 · Cited by 8
Mittal, N., Sehray, V., Mittal, R., & Singh, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174320 · Cited by 8
Shoar, S., Shah, A. A., Ikram, W., Farooq, N., Udoh, A. I., Tabibzadeh, E., Khavandi, S., & Khavandi, S. (2021) · American Journal of Cardiovascular Disease · Cited by 8
Primary Prevention of CVD with Aspirin: Benefits vs Risks
Weisman (2021) · The Journal of Family Practice · doi:10.12788/jfp.0222 · Cited by 9
Lam, B. C. C., Chew, D. P., & Pasquale, C. G. D. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.015 · Cited by 7
New therapies for the treatment of heart failure with preserved ejection fraction
Meier, M., & Pierce, K. N. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac129 · Cited by 7
Role of Ertugliflozin in the Management of Diabetes Mellitus
Totade, M., & Gaidhane, S. (2022) · Cureus · doi:10.7759/cureus.31404 · Cited by 9
“Food and Drug Administration agency (FDA) and other regulatory bodies in Europe and Asia (European Medicines Agency, National Medical Products Administration) have licensed or approved for the oral use of ertugliflozin for regulating blood glucose levels in individuals with T2DM [1-2].”
BackgroundMechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
Lytvyn, Y., Scholtes, R. A., Boorsma, E. M., Sridhar, V. S., Kugathasan, L., Liu, H., Lovblom, L. E., Handoko, M. L., Mosterd, C. M., Floras, J. S., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70275 · Cited by 7
“Importantly, clinical trials have demonstrated that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce mortality and HF risk, as well as decrease the risk of progressive diabetic kidney disease (DKD) (Cannon et al., 2020; Neal et al., 2017; Zinman et al., 2015).”
Self-citationSGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
Luo, T., Zhang, L., Tu, K., Li, G. L., Su, H., Gong, G., Huang, Y., Li, M., & Yang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589341 · Cited by 9
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
“The trajectory of weight gain in this study was relatively smaller than STEP 1, possibly due to the smaller amount of weight loss in this group but also due to continued lifestyle intervention support after medical withdrawal as mentioned above [51].”
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Lewellyan, C. M., Spoutz, P. M., Schaefer, M. G., & Patterson, M. E. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5496 · Cited by 7
Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes
Katsiki, N., Kazakos, K., & Triposkiadis, F. K. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2143263 · Cited by 6
Heart failure with reduced ejection fraction: What’s new in the 2022 guideline?
Kittleson, M. M. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22101 · Cited by 6
Wang, X., Zhang, X., Zhang, W., Li, J., Weng, W., & Li, Q. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2409258 · Cited by 6
Liu, S., Ke, J., Feng, X., Wang, Z., Wang, X., Yang, L., & Zhao, D. (2024) · Journal of Diabetes Research · doi:10.1155/2024/2431441 · Cited by 6
Wong, H. J., Lin, N., Teo, Y. N., Syn, N. L. X., Teo, Y. H., & Sia, C. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00640-w · Cited by 8
“Three of the eight included SGLT2 inhibitor studies published KM curves for the primary outcome of cardiovascular mortality [10, 27, 30]; however, none of the included metformin studies published relevant KM curves.”
InfluentialWang, D., Mo, Y., Tan, X., Xie, J.-Y., Wang, H., & Wen, F. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02289-y · Cited by 7
Huang, X., Jiang, D., Feng, X., & Fang, Z.-M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176698 · Cited by 6
Handling the sugar rush: the role of the renal proximal tubule
Spellman, M., Assaf, T., Nangia, S., Fernandez, J., Nicholson, K. C., & Shepard, B. D. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00265.2024 · Cited by 6
Hoda, F., Negi, H., Saini, D., Arshad, M., Sidra, Z., Kumar, R., Habib, A., Akhtar, M., & Najmi, A. K. (2024) · Exploration of Medicine · doi:10.37349/emed.2024.00255 · Cited by 11
Type 2 diabetes, heart failure and the treatment of their comorbidity
Wang, S., & Li, S. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09264-4 · Cited by 6
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus
AlHabeeb, W., Elasfar, A., Kinsara, A. J., Aljizeeri, A. H., Jelaidan, I., Alghalayini, K. W., AlKheraiji., M. F., Akbar, M. A. J., Lawand, S., Alyousif, S. M., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1407 · Cited by 11
Piccirillo, F., Lanciotti, M., Nusca, A., Frau, L., Spanò, A., Liporace, P., Ussia, G. P., & Grigioni, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052103 · Cited by 6
“Moreover, therapy with SGLT2is is associated with a reduction in MACEs in patients with type 2 diabetes mellitus (T2DM) [5,11–13].”
Ge, J. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000112 · Cited by 7
The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases
Moustafa, B., & Trifan, G. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01425-7 · Cited by 7
Strojek, K., Pandey, A. S., Dell, V., Sisson, M., Wang, S., Huyck, S. B., Liu, J., & Gantz, I. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01018-w · Cited by 7
“Although the VERTIS CV study and hence this substudy were conducted in patients with established ASCVD, the results of this substudy are likely to be relevant to the general population of T2DM patients without established CVD.”
MethodResultSelf-citationZhang, F., Wang, W., & Hou, X. H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13688 · Cited by 7
Glucose-lowering therapy in patients undergoing percutaneous coronary intervention
Johansson, I., Dicembrini, I., Mannucci, E., & Cosentino, F. (2021) · EuroIntervention · doi:10.4244/eij-d-20-01250 · Cited by 8
Self-citationChatzis, D., Kolokathis, K., Magounaki, K., Chatzidakis, S., Avramidis, K., Leopoulou, M., Angelopoulos, T. P., & Doupis, J. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.92 · Cited by 8
“P MACE events, compared with 11.6% in the control group (851 patients).32 Additionally, the TECOS trial results showed neutral findings regarding the secondary outcomes such as non-fatal stroke events and hospitalization for HF.32 Moreover, the CV profile of saxagliptin in patients with DM was examined in the SAVOR-TI…”
MethodInfluentialCurrent Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction
Dahal, R. K., Nickel, N. P., Mukherjee, D., & Alkhateeb, H. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x22666220630164630 · Cited by 7
Proietti, R., & Lip, G. Y. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14818 · Cited by 6
Liang, B., Li, R., Zhang, P., & Gu, N. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10302-4 · Cited by 6
“5-year follow-up of 8246 patients (5499 patients in the ertugliflozin group and 2747 patients in the placebo group), it is concluded that ertugliflozin was non-inferior to placebo concerning major adverse cardiovascular events (12% reduction in the ertugliflozin group and 12% reduction in the placebo group) [34].”
BackgroundKale, A., Sharma, A., Anders, H., & Gaikwad, A. B. (2022) · Current Diabetes Reviews · doi:10.2174/1573399819666220816145907 · Cited by 7
Dagogo-Jack, S. E., Frederich, R. C., Liu, J., Cannon, C. P., Shi, H. H., Cherney, D. Z. I., Cosentino, F., MASIUKIEWICZ, U. S., Gantz, I., & Pratley, R. E. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac764 · Cited by 6
Self-citationPanchal, R., Nguyen, D. T., Ghule, P., Li, N., Giannouchos, T. V., Pan, R. J., BISKUPIAK, J. E., Britton, L., Nohavec, R., Slager, S. L., et al. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.2.139 · Cited by 7
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Sanz‐Cánovas, J., Ricci, M., Cobos-Palacios, L., Sampalo, A. L., Hernández-Negrín, H., Vázquez-Márquez, M., Mancebo-Sevilla, J. J., Álvarez-Recio, E., Lopez-Carmona, M. D., Velasco, M. Á. P., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2402036 · Cited by 6
Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
Bernardi, M., Spadafora, L., Galli, M., Biondi‐Zoccai, G., & Sabouret, P. F. (2023) · Archives of Medical Science · doi:10.5114/aoms/160006 · Cited by 7
“In the same therapeutic class, ertugliflozin was evaluated in the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV), which randomized 8,246 patients with type 2 diabetes and atherosclerotic cardiovascular disease to ertugliflozin or placebo [10].”
The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
Gitto, M., Villaschi, A., Federici, M., Condorelli, G., & Stefanini, G. G. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230217143324 · Cited by 6
Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Yerra, V. G., & Connelly, K. A. (2024) · Physiology · doi:10.1152/physiol.00008.2024 · Cited by 7
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Rhee, E., Kim, M. K., & Lee, W. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.106 · Cited by 6
“CV) study, which evaluated the long-term effects of ertugliflozin on CV and renal outcomes in patients with T2DM, were published [16].”
BackgroundZwart, K., Velthuis, S., Polyukhovych, Y. V., Mosterd, A., Smidt, L. C. A., Serné, E. H., van Raalte, D. H., Elders, P. J. M., Handoko, M. L., & Oldenburg-Ligtenberg, P. C. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01580-9 · Cited by 7
Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura
González, V. (2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.2.8 · Cited by 11
Onyali, C. B., Anim-Koranteng, C., Shah, H. E., Bhawnani, N., Ethirajulu, A., Alkasabera, A., & Mostafa, J. A. (2021) · Cureus · doi:10.7759/cureus.17452 · Cited by 9
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 11
2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
Chiang, C., Ueng, K., Chao, T., Lin, T., Wu, Y., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2021) · JACC Asia · doi:10.1016/j.jacasi.2021.08.003 · Cited by 7
“Cannon et al (20) VERTIS CV (n 1⁄4 8,246) Ertugliflozin Diabetes 4 NR 4 Y 4 4”
BackgroundMethodInfluentialKroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Nelson, A. J., Harrington, J., Kolkailah, A. A., Pagidipati, N. J., & McGuire, D. K. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.007 · Cited by 6
Self-citationPovar-Echeverría, M., Méndez‐Bailón, M., Martín‐Sánchez, F. J., Montero-Pérez-Barquero, M., Trullàs, J. C., & Miró, Ò. (2023) · Revista Clínica Española · doi:10.1016/j.rce.2023.07.007 · Cited by 6
Management of Type 2 Diabetes Mellitus
Kawa, L. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002478 · Cited by 7
MacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 8
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Kataria, A., & Argyropoulos, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_25 · Cited by 7
SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics
DEEDWANIA, P. C. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00495-5 · Cited by 6
Are All SGLT2 Inhibitors Created Equal?
Gregg, L. P., & Navaneethan, S. D. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09720721 · Cited by 6
Birker, S., Meier, J. J., & Nauck, M. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-25296-x · Cited by 6
Type 2 diabetes mediated heart failure: focus on early recognition and clinical strategies
Chen, X., Li, W. S., Zheng, J.-W., Huang, M., Wang, J., & Wu, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1630686 · Cited by 6
Zhang, Z., Li, Y., Gu, H. F., & Li, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118837 · Cited by 5
Ahmed, A. A. O., Ahmed, O., Ahmed, R. A. O., Ahmed, R. A. O., Mohammed, M. A. E. A., Ahmed, Y., Abbas, M., Ibrahim, M. A. A., Abakar, M. E. M., Dahab, K. E. M., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05455-4 · Cited by 8
“Trials with large sample sizes as randomized controlled trials (RCTs), have demonstrated that both drug classes reduce major adverse cardiovascular events (MACE), heart failure hospitalizations, and improve renal outcomes in high-risk patients with diabetes [3–14].”
InfluentialZawadka, M., Taguiam, E., Lê, M., Sanjanwala, R., Liu, S., Shah, A. H., & Kunutsor, S. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70411 · Cited by 6
SGLT2 Inhibitors After Myocardial Infarction: Evidence, Mechanisms and Gaps in Knowledge
Buonpane, A., Ciardetti, M., Trimarchi, G., Scalone, G., Coceani, M. A., Pastormerlo, L. E., Marchi, F., Paradossi, U., Berti, S., Passino, C., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062260 · Cited by 6
“Ertugliflozin in VERTIS-CV [15] showed neutral effects on atherosclerotic endpoints but consistently reduced heart failure hospitalizations, whereas sotagliflozin in SCORED [16] further supported a class effect on heart failure prevention in patients with diabetes.”
From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies
Modica, R., Liccardi, A., Zamponi, V., Gagliardi, A., Nistor, A., Veroi, G., Arecco, A., Faggiano, A., & Colao, A. (2026) · Endocrine · doi:10.1007/s12020-026-04644-1 · Cited by 5
Interventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 6
Ito, S., Nakajima, Y., Fukuda, H., Izumi, C., Nakazawa, G., Yamashita, H., Matsuhisa, H., Inoko, M., Toyoda, S., Takiuchi, S., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07576-y · Cited by 5
“However, in the VERTIS CV trial, ertugliflozin did not improve the composite of CV death or hospitalization for HF [16].”
Empagliflozin: Primus Inter Pares Among Sodium–Glucose Cotransporter-2 Inhibitors?
Biondi‐Zoccai, G., Frati, G., Peruzzi, M., & Booz, G. W. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001605 · Cited by 5
Yamashita, I., Fujisaki, T., Romeo, F. J., Sueta, D., Yamamoto, E., & Tsujita, K. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001659 · Cited by 5
Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer
Aber, E. R., Carducci, M. A., Paller, C. J., Denmeade, S. R., Rourke, K., Marshall, C. H., & Markowski, M. C. (2024) · The Prostate · doi:10.1002/pros.24841 · Cited by 5
Cardiovascular Outcomes With Antidiabetic Drugs in People With Type 2 Diabetes and a Prior Stroke
Bae, J. H., Choi, J., Kim, N. H., & Kim, S. G. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.015 · Cited by 5
Dutta, D., Nagendra, L., Kamrul-Hasan, A. B. M., & Mahajan, K. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.1 · Cited by 6
Early prescription of SGLT2i for acute patient care: from current evidence to future directions
Ricci, F., Saraullo, S., Boccatonda, A., Sorella, A., Cipollone, A., Simeone, P., Gallina, S., Santilli, F., Cipollone, F., & D’Ardes, D. (2025) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2025.103081 · Cited by 6
Guo, R., Pandey, A., Chandramouli, C., Wu, M., Cai, A., Liu, Y., Ren, Q. W., Huang, J., Zhang, J.-R., Gu, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16509 · Cited by 5
“13,14,16 FIGURE 2 Cardiovascular and renal outcomes in patients initiating SGLT2 inhibitors vs DPP-4 inhibitors after 1:1 PSM. SGLT2, sodium-glucose transporter-2; DPP-4, dipeptidyl peptidase 4; MACE, major adverse cardiovascular events; SRE, serious renal events; AMI, acute myocardial infarction;…”
Bai, J., Zhang, L., He, L., & Zhou, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1613640 · Cited by 7
Dong, H., Guo, Q., Cai, M., Guo, M., Liu, Y., & Cheng, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178077 · Cited by 5
Warden, B. A., Steiner, J., Camacho, A., Nguyen, K. A., Purnell, J. Q., Duell, P. B., Craigan, C., Osborn, D., & Fazio, S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100183 · Cited by 6
Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients
Jenssen, T. G. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000749 · Cited by 5
Almas, T., Alsufyani, R., Jiffry, R., Alsubai, A. K., Almesri, A., Ali, S. A., Baqal, O. J., Malik, J., Ahmed, T., & Rana, M. N. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101508 · Cited by 5
Lee, M.-C., Hua, Y., Yang, C., Kuo, F., Chang, W., Tang, H., Toh, H. S., Lin, Y., Chen, S.-Y., Chang, H., et al. (2022) · Medicine · doi:10.1097/md.0000000000032489 · Cited by 5
“Ten identified RCTs included dapagliflozin (the DEFINE-HF, DECLARE-TIMI 58, and DAPA-HF trials),[8,9,27] canagliflozin (the CANVAS PROGRAM trial),[6] empagliflozin (the EMPARESPONSE-AHF, EMPA-REG OUTCOME, and EMPERORReduced trials),[7,10,28] ertugliflozin (the VERTIS-CV trial),[29] and sotagliflozin (the SOLOIST-WHF t…”
BackgroundEnea, I., & Martelli, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113652 · Cited by 7
Boutsikos, I., Beltsios, E. T., Schmack, B., Pantazopoulos, I. N., & Chatzis, D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.12 · Cited by 5
“40,69,93,97,98 Ongoing research Although SGLT2i have shown beneficial effects mostly for patients with HF, independent of their glycaemic status, there are many clinical scenarios that have not yet been addressed.”
Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in db/db mice
Desai, D. A., Baby, A., Ananthamohan, K., Green, L. C., Arif, M., Duncan, B. C., Kumar, M., Singh, R. R., Koch, S. E., Natesan, S., et al. (2024) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2024.100075 · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
“The amputation rate with placebo was also 1.6 % [145].”
InfluentialRastogi, A., Collins, A. K., Kelepouris, E., Kotzker, W. R., Middleton, J. P., Rajpal, M., Roy‐Chaudhury, P., & Chertow, G. M. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241259905 · Cited by 7
Takahashi, Y., Minagawa, K., Nagashima, T., Hayakawa, T., Akimoto, H., & Asai, S. (2024) · Clinical and Translational Science · doi:10.1111/cts.70088 · Cited by 10
“8,28 29–32 These findings strongly suggest that SGLT2 inhibitors are a valuable treatment option for a broad range of patients with heart failure, including those with and without diabetes, and with varying degrees of ejection fraction.”
Fatima, E., Irfan, H., Fatima, F., Jain, J., Rehman, O. U., Sehar, A., Ahmad, B., Kumari, S., & Akilimali, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003357 · Cited by 6
“…death or hospitalization due to heart failure as compared to placebo Cardiovascular outcomes with ertugliflozin in type 2 diabetes 2020 VERTIS-CV [30] Ertugliflozin Ertugliflozin demonstrated non-inferiority to placebo in terms of major adverse cardiovascular events (MACE) Sotagliflozin in…”
Ryder, R. E. J., Abdul-Ghani, M. A., & DeFronzo, R. A. (2020) · British Journal of Diabetes · doi:10.15277/bjd.2020.276 · Cited by 5
Seferovic, P. M., Polovina, M. M., Milinković, I., Anker, S. D., Rosano, G. M. C., & Coats, A. J. S. (2021) · International Journal of Heart Failure · doi:10.36628/ijhf.2021.0013 · Cited by 5
SGLT2-Inhibitoren: Was gibt es Neues?
Dumann, E., & Menne, J. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00511-4 · Cited by 6
Gitto, M., Vrachatis, D. A., Condorelli, G., Papathanasiou, K. A., Reimers, B., Deftereos, S. G., & Stefanini, G. G. (2021) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525719666210809121016 · Cited by 5
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 8
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.